论文部分内容阅读
目的 探讨Bc1-2和C-myc在阴茎癌组织中的表达及其意义。方法应用免疫组化法(SABC)对49例阴茎癌 组织和9例正常阴茎组织标本进行bc1-2和 c-myc蛋白产物检测。结果 49例阴茎癌标本中26例be1-2检测阳性 (53.1%):25例c-myc检测阳性(51%),9例正常阴茎2例be1-2检测阳性(22.2%);C-myc未见阳性染色。Be1-2阳性率 在高、中、低分化肿瘤中分别为 83.3%、55.6%、31.6%。在临床Ⅰ/Ⅱ期和Ⅲ/Ⅳ期肿瘤中分别是69%,30%。 c-myc阳性率在高、 中、低分化肿瘤中分别为25%,50%,68.4%。在临床Ⅰ/Ⅱ期和Ⅲ/Ⅳ期肿瘤中分别为34.5%,75%。显示be1-2表达阳性率与阴 茎癌的病理分级和临床分期呈负相关(P<0.05),而c-myc阳性表达率与阴茎癌的病理分级和临床分期呈正相关(P<0.05)。 结论 be1-2,c-myc蛋白的表达与阴茎癌组织病理分级和临床分期密切相关,be1-2和 c-myc可以作为阴茎癌的瘤标。
Objective To investigate the expression of Bcl-2 and C-myc in penile cancer and its significance. Methods The expression of bc1-2 and c-myc in 49 cases of penile cancer tissues and 9 cases of normal penile tissues were detected by immunohistochemistry (SABC). Results Of the 49 cases of penile cancer, 26 cases were positive for be1-2 (53.1%), 25 cases were positive for c-myc (51%) and 2 cases were positive for be1-2 (22.2%) in 9 cases of normal penis. ; C-myc no positive staining. The positive rate of Be1-2 was 83.3%, 55.6% and 31.6% in high, moderate and poorly differentiated tumors respectively. In clinical stage I / II and III / IV tumors were 69%, 30%. The positive rate of c-myc was 25%, 50% and 68.4% in high, moderate and poorly differentiated tumors respectively. In clinical stage I / II and stage III / IV tumors were 34.5%, 75%. The positive rate of be1-2 expression was negatively correlated with the pathological grade and clinical stage of penile cancer (P <0.05), while the positive expression rate of c-myc was positively correlated with the pathological grade and clinical stage of penile cancer (P <0.05). 05). Conclusion The expression of be1-2 and c-myc proteins is closely related to the pathological grade and clinical stage of penile cancer tissues. Be1-2 and c-myc can be used as tumor markers of penile cancer.